ClinicalTrials.govpublic full text
Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
non-small-cell lung carcinoma, erlotinib, dasatinib, epidermal growth factor receptor (egfr), tyrosine kinase, nsclc, pharmacokinetics (pk), lung, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 840475
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.